National Institute for Health and Care Excellence. Guideline: type 2 diabetes in adults: management. London: National Institute for Health And Care Excellence (Nice). Copyright National Institute For Health And Care Excellence; 2015.

American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S98–110.

Article  Google Scholar 

Moran G, Bakhai C, Song S, Agwu J. Type 2 diabetes: summary of updated nice guidance. BMJ Br Med J. 2022. https://doi.org/10.1136/bmj.o775.

Article  Google Scholar 

Bonora B, Avogaro A, Fadini G. Extraglycemic effects of Sglt2 inhibitors: a review of the evidence. Diabet Metab Syndr Obes. 2020;13:161–74.

Article  CAS  Google Scholar 

Filippatos T, Panagiotopoulou T, Elisaf M. Adverse effects of Glp-1 receptor agonists. Rev Diabet Stud. 2014;11(3–4):202–30.

Article  PubMed  Google Scholar 

Lin Y, Wang T-H, Tsai M-L, Wu V-C, Tseng C-J, Lin M-S, et al. The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovasc Diabetol. 2023. https://doi.org/10.1186/s12933-023-01793-9.

Article  PubMed  PubMed Central  Google Scholar 

Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al. Glp-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021. https://doi.org/10.3389/fendo.2021.721135.

Article  PubMed  PubMed Central  Google Scholar 

Faillie J, Yu O, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474–81.

Article  PubMed  Google Scholar 

He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nauck M, Muus Ghorbani M, Kreiner E, Saevereid H, Buse J. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the leader randomized trial. Diabetes Care. 2019;42(10):1912–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keller J, Trautmann M, Haber H, Tham L, Hunt T, Mace K, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179(1–3):77–83.

Article  CAS  PubMed  Google Scholar 

He L, Wang J, Li Z, Li Y, Zhang H. Dipeptidyl peptidase 4 inhibitors and gallbladder or biliary diseases: data from the U.S. Food and Drug Administration adverse event reporting system. Diabetes Care. 2022;46(2):E72–3.

Article  Google Scholar 

Moses R, Round E, Shentu Y, Golm G, Oneill EA, Gantz I, et al. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2016;8(5):701–11.

Article  CAS  PubMed  Google Scholar 

Rosenstock J, Kahn S, Johansen O, Zinman B, Espeland M, Woerle H, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the Carolina randomized clinical trial. JAMA. 2019;322(12):1155–66.

Article  CAS  PubMed  Google Scholar 

Rosenstock J, Perkovic V, Johansen O, Cooper M, Kahn S, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the Carmelina randomized clinical trial. JAMA. 2019;321(1):69–79.

Article  CAS  PubMed  Google Scholar 

Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

Article  CAS  PubMed  Google Scholar 

He L, Wang J, Ping F, Yang N, Huang J, Li W, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. BMJ. 2022;377:E068882.

Article  PubMed  PubMed Central  Google Scholar 

Herrett E, Gallagher A, Bhaskaran K, Forbes H, Mathur R, Van Staa T, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36.

Article  PubMed  PubMed Central  Google Scholar 

Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: clinical practice research datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740.

Article  PubMed  PubMed Central  Google Scholar 

Herrett E, Thomas S, Schoonen W, Smeeth L, Hall A. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nf K, Se H, Pw R. Validity of diagnostic coding within the general practice research database: a systematic review. Br J Gen Pract. 2010;60(572):E128–36.

Article  Google Scholar 

Jick H, Jick S, Derby L. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J. 1991;302(6779):766–8.

Article  CAS  Google Scholar 

Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: hospital episode statistics admitted patient care (HES APC). Int J Epidemiol. 2017;46(4):1093.

Article  PubMed  PubMed Central  Google Scholar 

National Health Service. Hospital episode statistics (HES). Available from https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics.

Office for National Statistics. Deaths. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.

Wexler D. Management of persistent hyperglycemia in type 2 diabetes mellitus. In: Nathan D, Mulder J, editors. Up to date. Waltham, MA: Up to date; 2021.

Google Scholar 

Wilkinson S, Douglas I, Stirnadel-Farrant H, Fogarty D, Pokrajac A, Smeeth L, et al. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017. BMJ Open. 2018;8(7):E022768.

Article  PubMed  PubMed Central  Google Scholar 

Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:L5657.

Article  PubMed  Google Scholar 

White I, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28(15):1982–98.

Article  PubMed  PubMed Central  Google Scholar 

Pizzimenti V, Giandalia A, Cucinotta D, Russo G, Smits M, Cutroneo P, et al. Incretin-based therapy and acute cholecystitis: a review of case reports and eudravigilance spontaneous adverse drug reaction reporting database. J Clin Pharm Ther. 2016;41(2):116–8.

Article  CAS  PubMed  Google Scholar 

Woronow D, Chamberlain C, Niak A, Avigan M, Houstoun M, Kortepeter C. Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food And Drug Administration. JAMA Intern Med. 2022;182(10):1104–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000;12(12):1347–52.

Article  CAS  PubMed  Google Scholar 

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.

Article  PubMed  Google Scholar 

Gallwitz B. Clinical use of Dpp-4 inhibitors. Front Endocrinol (Lausanne). 2019. https://doi.org/10.3389/fendo.2019.00389.

Article  PubMed  Google Scholar 

Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology. 2007;133(1):244–55.

Article  CAS  PubMed  Google Scholar 

Chen B, Zhao W, Dong J, Sima H. Expression of Glp-1r protein and its clinical role in intrahepatic cholangiocarcinoma tissues. Mol Biol Rep. 2014;41(7):4313–20.

Article  CAS  PubMed  Google Scholar 

Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist protects cholangiocytes from apoptosis. Gut. 2009;58(7):990–7.

Article  CAS  PubMed  Google Scholar 

Nexøe-Larsen C, Sørensen P, Hausner H, Agersnap M, Baekdal M, Brønden A, et al. Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity. Diabetes Obes Metab. 2018;20(11):2557–64.

Article  PubMed  PubMed Central  Google Scholar 

Gether I, Nexøe-Larsen C, Knop F. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. J Clin Endocrinol Metab. 2019;104(7):2463–72.

Article  PubMed  Google Scholar 

Rehfeld J, Knop F, Asmar A, Madsbad S, Holst J, Asmar M. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of Glp-1-derived drugs.